Clinical trials: Acute Treatment of Migraine
Acute Migraine
Chordate System S020 Acute Migraine Clinical Investigation
The main purpose of the study is to evaluate the impact of treatment with the Chordate System S020 (medical device) on acute migraine headache pain.
- Trial name
- Amici (NCT02185703)
- Testing
- Chordate System S020 in treatment mode
- Where
- 9 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Chordate Medical
Vestibular Migraine, Dizziness
Chinese Real-world Study of Treatment of Vestibular Migraine
Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment.
- Conditions
- Vestibular Migraine, Dizziness, Vertigo
- Trial name
- NCT07203248
- Testing
- CGRP R Inhibitor; CGRP Inhibitor, none-CGRP
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Migraine
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with…
- Trial name
- NCT04161807
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Theranica
Headache
Ketamine for Acute Migraine in the Emergency Department
This research study will be a prospective, randomized, double-blind, placebo-controlled trial. Because ketamine has yet to be directly studied as treatment for acute migraine headache in the emergency department, the research…
- Trial name
- NCT02697071
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Carilion Clinic
Migraine With Aura, Migraine Without Aura
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.
- Trial name
- ATOM (NCT05214001)
- Testing
- Almotriptan 12.5 Mg Oral Tablet, Ubrogepant 50Mg Tab
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Messoud Ashina, MD
Migraine
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose, placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550 mg) in the acute treatment of migraine.
- Trial name
- RELIEF (NCT04384367)
- Testing
- Rizatriptan 10 mg + Naproxen 550mg, Maxalt 10Mg Tablet, Flanax 550mg
- Where
- 2 sites in Brazil
- Volunteers
- 2,068 people
- Sponsor
- Eurofarma Laboratorios S.A.
Migraine With Typical Aura
Study With Migraid Device in Acute, Early Treatment of Migraine With Typical Aura
The purpose of the study was to assess the efficacy of Migraid in terms of preventing headaches in patients with migraine with typical aura.
- Trial name
- NCT00126035
- Testing
- Migraid
- Where
- Netherlands
- Volunteers
- 134 people
- Sponsor
- Profess Medical Consultancy
Migraine With or Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
- Trial name
- ANODYNE-1 (NCT03061734)
- Testing
- Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Allodynic Therapeutics, Inc
Acute Treatment of Migraine
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack.
- Trial name
- NCT07609914
- Testing
- Rimegepant
- Where
- 24 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Pfizer
Migraine
A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine
This is a research study looking at Migranal (study drug) in the treatment of two migraine attacks in patients who have a history of cutaneous allodynia (pronounced q-tay-nee-us al-o-din-ee-a).
- Trial name
- NCT00335777
- Testing
- Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Thomas Jefferson University
Migraine
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents.
- Trial name
- NCT00210483
- Testing
- almotriptan malate
- Volunteers
- 866 people
- Sponsor
- Janssen-Ortho LLC
Migraine
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following…
- Trial name
- NCT04068051
- Testing
- AXS-07
- Where
- 51 sites in United States
- Volunteers
- 706 people
- Sponsor
- Axsome Therapeutics, Inc.